Eli Lilly Leads Weight Loss Market with Soaring Zepbound Sales
Eli Lilly’s dominance in the weight-loss drug market with Zepbound (tirzepatide) is well-documented, but a far more transformative opportunity lies in its pipeline: a breakthrough Alzheimer’s therapy poised to redefine ... Read More